$BIO

Citigroup has lowered its rating on Bio-Rad Laboratories (BIO) to Neutral and reduced its price target from $375 to $300, citing concerns over the company's process chromatography segment and diagnostic operations in China. Despite this, Bio-Rad recently expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies, enhancing its capabilities in drug development and monitoring. The article suggests that while Bio-Rad has investment potential, other AI stocks may offer greater upside with less risk.